Article

Amgen's T-Vec to Receive FDA Decision Today

Author(s):

The vaccine, approved in Europe last week, is now awaiting approval in the United States.

Imlygic, or talimogene laherparepvec, a genetically modified herpes simplex type 1 virus developed by Amgen to be injected directly into tumors, where it replicates and forces tumor cell rupture, is waiting for FDA's decision. The NDA for this virus-based treatment has been submitted for melanoma.

An advisory panel for the FDA reviewed data from the phase 3 OPTiM trial and voted 22-1 in favor of approval back in April 2015. Now the FDA has to consider this panel's advice before it's decision later today.

Meanwhile, the European Medical Agency approved T-Vec for use in patients with unresectable melanoma that has not metastatized just last week.

Read more here.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
EHA 2025 Congress Recap | Image Credit: Venngage
Coral Omene, MD, PhD, sitting for a vieo interview
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Dr Marina Kremskayana
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo